Zhongjing Pukang Completes ￥10M Pre-A Round of Financing

According to VCBeat, Zhongjing Pukang (Beijing) Pharmaceutical Technology Co., Ltd. ("Zhongjing Pukang") has completed the Pre-A round financing of tens of millions yuan, with participation from Tengye Ventures and the angel round investor Taiyu Capital. Optimas Capital acted as the exclusive financial consultant. Proceeds from this round will mainly be used for product approval, clinical researches, and commercialization.

Founded in 2016 by Dr. Dai Xudong, Zhongjing Pukang has rapidly built its technology platform based on multi-omics data and disease mechanisms with mass spectrometry as the detection method, and developed early diagnosis products for major diseases such as cancer. At present, the main products of the company are used for screening colorectal tumors and gastrointestinal tumors. Zhongjing Pukang has established cooperation with many top hospitals, universities, and research institutes in China.

At the end of 2017, Zhongjing Pukang got the investment from Taiyu Capital in the angel round. It is committed to the transformation and application of the B-GPS system, combining cutting-edge scientific research results with clinical needs, and developing early diagnosis products for a variety of diseases such as colorectal cancer. 

The mass spectrometry blood test of Zhongjing Pukang only needs to take 100 microliters of blood, and intestinal polyps and tumors can be found through the detection of specific cell metabolites and intestinal flora metabolites, therefore patients can be treated by colonoscopy in a timely manner. Through early detection, the survival rate can be significantly improved and the treatment cost can also be reduced.

Zhongjing Pukang has cooperated with Peking Union Medical College Hospital, Peking University Health Science Center, Cancer Hospital Chinese Academy of Medical Sciences, etc. The company hopes to bring innovations in clinical diagnosis through the company's platform, so that precision medicine can be popularized to a greater extent.

Tengye Ventures focuses on early-stage investments in high-tech start-ups engaged in biomedicine and healthcare, TMT, new energy, energy conservation and environmental protection, advanced manufacturing, and high-end equipment. It manages six funds and has invested in more than 30 enterprises. 

Taiyu Capital focuses on equity investment in the early and growth stage in the healthcare industry, such as medical devices, health food, CRO, and medical-related service enterprises.